Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika
About Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
6
Pfizer
6
Arena Pharmaceuticals
1
Cortendo AB
1
Gan and Lee Pharmaceuticals, USA
1
Genentech, Inc.
1
Genmab
1
Gilead Sciences
1
HRA Pharma
1
Ipsen
1
Janssen Research & Development, LLC
1
Clinical Trials at Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika
During the past decade, Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 8 clinical trials were completed, i.e. on
average, 61.5% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 2 clinical trials were completed. i.e. 40%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
2008-10-16
2029-09-20
Recruiting
720
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
2010-01-26
2017-08-07
Completed
452
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)
2010-07-31
2016-09-16
Completed
1,095
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
2011-02-01
2015-02-01
Completed
250
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
2012-06-06
2018-07-26
Completed
106
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
2012-05-17
2020-02-19
Completed
2,577
Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis; Efficacy, Safety and Tolerability Study
2012-04-01
2014-01-01
Terminated
150
An Observational Study of First-Line Capecitabine Based Chemotherapy in Participants With Metastatic Colorectal Cancer
2011-07-01
2014-12-01
Completed
882
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Pfizer" with 6 trials
sponsored, "Arena Pharmaceuticals" with 1 trials sponsored, "Cortendo AB" with 1 trials sponsored and "Gan and Lee Pharmaceuticals, USA"
with 1 trials sponsored. Other sponsors include 2 different institutions and
companies that sponsored additional 12 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika"
#1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "Hoffmann-La Roche" with 1 trials as a collaborator and "PRA Health Sciences" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were
collaborators in the rest 5 trials.
Clinical Trials Conditions at Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika
According to Clinical.Site data, the most researched conditions in "Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika" are
"Ulcerative Colitis" (6 trials), "Breast Cancer" (2 trials), "Colorectal Cancer" (2 trials), "Crohn's Disease" (2 trials) and "Acute Myeloid Leukemia" (1 trials). Many other conditions were trialed in "Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika" in a lesser frequency.
Clinical Trials Intervention Types at Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika
Most popular intervention types in "Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika" are "Drug" (19 trials), "Biological" (2 trials), "Combination Product" (1 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (4 trials), "Etrasimod" (3 trials), "Capecitabine" (2 trials), "Chemotherapy" (2 trials) and "PF-06651600" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika
The vast majority of trials in "Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika" are
21 trials for "All" genders and 1 trials for "Female" genders.
Clinical Trials Status at Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika
Currently, there are NaN active trials in "Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika".
undefined are not yet recruiting,
5 are recruiting,
4 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 12 completed trials in Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika, 0 "Phase 1"
clinical trials were conducted, 6 "Phase 2" clinical
trials and 13 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 0 trials that are defined as “Not Applicable".